Losartan prevents the development of the pro-inflammatory monocytes CD14+CD16+ in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 27, Issue 7, 2012, Pages 2907-2912

  Merino, Ana ^a,b   Alvarez Lara, Maria Antonia ^a,b,c   Ramirez, Rafael ^a,b   Carracedo, Julia ^a,b   Martin Malo, Alejandro ^a,b,c   Aljama, Pedro ^a,b,c  

^a Instituto de Salud Carlos III   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

CD14+CD16+ monocytes; haemodialysis; losartan

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CARVEDILOL; CD14 ANTIGEN; CD16 ANTIGEN; DOXAZOSIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 4; LOSARTAN;

ADULT; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HEMODIALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPAIN;

ANTIGENS, CD14; ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-4; LEUKOCYTE COUNT; LOSARTAN; MALE; MIDDLE AGED; MONOCYTES; PROGNOSIS; RECEPTORS, IGG; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84863755809     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr767     Document Type: Article

References (30)

1. Chertow GM, Goldstein-Fuchs DJ, Lazarus JM et al. Prealbumin, mortality and cause-specific hospitalization in hemodialysis patients. Kidney Int 2005; 68: 2794-2800.
2. Panichi V, Maggiore U, Taccola D et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in hemodialysis patients. Nephrol Dial Transplant 2004; 19: 1154-1160.
3. Barreto DV, Barreto FC, Liabeuf S et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and predialysis patients with chronic kidney disease. Kidney Int 2010; 77: 550-556.
4. Koc M, Toprak A, Arikan H et al. Toll-like receptor expression in monocytes in patients with chronic kidney disease and haemodialysis: relation with inflammation. Nephrol Dial Transplant 2011; 26: 955-963.
5. Sester U, Sester M, Heine G et al. Strong depletion of CD14+CD16+ monocytes during hemodialysis treatment. Nephrol Dial Transplant 2001; 16: 1402-1408.
6. Merino A, Portolés J, Selgas R et al. Effect of different dialysis modalities on microinflammatory status and endothelial damage. Clin J Am Soc Nephrol 2010; 5: 227-234.
7. Buckner CM, Calderon TM, Willams DW et al. Characterization of monocyte maturation/differentiation that facilitates their transmigration across the blood-brain barrier and infection by HIV: implications for NeuroAIDS. Cell Immunol 2011; 267: 109-123.
8. Cairns AP, Crockard AD, Bell AL. The CD14+ CD16+ monocyte subset in rheumatoid arthritis and systemic lupus erythematosus. Rheumatol Int 2002; 21: 189-192.
9. Belge KU, Dayyani F, Horelt A et al. The proinflammatory CD14 +CD16+DR++ monocytes are the major source of TNF. J Immunol 2002; 168: 3536-3542.
10. Ramirez R, Carracedo J, Merino A et al. Microinflammation induces endothelial damage in hemodialysis patients: the role of convective transport. Kidney Int 2007; 72: 108-113.
11. Merino A, Nogueras S, Buendía P et al. Microinflammation and endothelial damage in hemodialysis. Contrib Nephrol 2008; 161: 83-88.
12. Guo S, Kowalewska J, Wietecha TA et al. Renin-angiotensin system blockade is renoprotective in immune complex-mediated glomerulonephritis. J Am Soc Nephrol 2008; 19: 1168-1176.
13. Kitazono T, Padgett RC, Armstrong ML et al. Evidence that angiotensin II is present in human monocytes. Circulation 1995; 91: 1129-1134.
14. Okamura A, Rakugi H, Oishi M et al. Upregulation of rennin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens 1999; 17: 537-545.
15. Kim JA, Berliner JA, Nadler JL. Angiotensin II increases monocyte binding to endothelial cells. Biochem Biophys Res Commun 1996; 226: 862-868.
16. Nahmod KA, Vermeulen ME, Raiden S et al. Control of dendritic cell differentiation by angiotensin II. FASEB J 2003; 17: 491-493.
17. Li L, Zhou N, Gong H et al. Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice. Hypertens Res 2010; 33: 1289-1297.
18. Tunçdemir M, Demirkesen O, Oztürk M et al. Antiapoptotic effect of angiotensin-II type-1 receptor blockade in renal tubular cells of hyperoxaluric rats. Urol Res 2010; 38: 71-80.
19. Kim MY, Baik SK, Park DH et al. Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model. J Gastroenterol 2008; 43: 889-896.
20. An J, Nakajima T, Kuba K et al. Losartan inhibits LPS-induced inflammatory signaling through a PPARgamma-dependent mechanism in human THP-1 macrophages. Hypertens Res 2010; 33: 831-835.
21. Ancuta P, Weiss L, Haeffner-Cavaillon N. CD14+CD16++ cells derived in vitro from peripheral blood monocytes exhibit phenotypic and functional dendritic cell-like characteristics. Eur J Immunol 2000; 30: 1872-1883.
22. Strawn WB, Ferrario CM. Angiotensin II AT1 receptor blockade normalizes CD11b+ monocyte production in bone marrow of hypercholesterolemic monkeys. Atherosclerosis 2008; 196: 624-632.
23. Sakuta T, Morita Y, Satoh M et al. Involvement of the renin-angiotensin system in the development of vascular damage in a rat model of arthritis: effect of angiotensin receptor blockers. Arthritis Rheum 2010; 62: 1319-1328.
24. Carracedo J, Merino A, Nogueras S et al. On-line hemodiafiltration reduces the proinflammatory CD14+CD16+ monocyte-derived dendritic cells: a prospective, crossover study. J Am Soc Nephrol 2006; 17: 2315-2321.
25. Schindler R, Beck W, Deppisch R et al. Short bacterial DNA fragments: detection in dialysate and induction of cytokines. J Am Soc Nephrol 2004; 15: 3207-3214.
26. Navarro MD, Carracedo J, Ramirez R et al. Bacterial DNA prolongs the survival of inflamed mononuclear cells in haemodialysis patients. Nephrol Dial Transplant 2007; 22: 3580-3585.
27. Merino A, Buendia P, Martin-Malo A et al. Senescent CD14+CD16 + monocytes exhibit proinflammatory and proatherosclerotic activity. J Immunol 2011; 186: 1809-1815.
28. Busca A, Saxena M, Kryworuchko M et al. Anti-apoptotic genes in the survival of monocytic cells during infection. Curr Genomics 2009; 10: 306-317.
29. Merino A, Nogueras S, García-Maceira T et al. Bacterial DNA and endothelial damage in haemodialysis patients. Nephrol Dial Transplant 2008; 23: 3635-3642.
30. Nahmod K, Gentilini C, Vermeulen M et al. Impaired function of dendritic cells deficient in angiotensin II type 1 receptors. J Pharmacol Exp Ther 2010; 334: 854-862.